ReviewFrontiers in pediatrics2023
Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis.
Review in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Impact of anti-VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta-analysis.Acta ophthalmologica · 2026Pooled it
- Comprehensive evaluation of risk factors for intraventricular hemorrhage in preterm neonates: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- Association of Fortification with Human Milk versus Bovine Milk-Based Fortifiers on Short-Term Outcomes in Preterm Infants-A Meta-Analysis.Nutrients · 2024Pooled it
- Risk Factors Influencing Neurodevelopmental Outcome and Survival in Preterm Infants: A Prospective Cohort Study.Children (Basel, Switzerland) · 2026Article
- Epidemiology and treatment trends of retinopathy of prematurity: a multi-center study involving four Asian centers and one European center (2016-2023).Japanese journal of ophthalmology · 2026Article
- Early autism risk factors: a cohort study of children born very preterm at 5-years.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity: The DROPROP Randomized Clinical Trial.JAMA pediatrics · 2026Article
- Neuroprognostication in infants born preterm at the limits of viability: assessment under uncertainty.Pediatric research · 2026Review
- Inpatient morbidities and medical technology use at 2 years among extremely preterm infants.Pediatric research · 2026Observational
- Very Preterm Infant Retinal Microanatomy at 36 Weeks' Postmenstrual Age and 2-Year Neurodevelopment.JAMA ophthalmology · 2026Article
- Epac1 deletion attenuates Müller glial pathological activation and mitigates retinal neurodegeneration in ischemia-induced retinopathy.Journal of advanced research · 2026Article
- Retinopathy of Prematurity and Neurodevelopmental and Quality-of-Life Outcomes at 10 Years of Age.American journal of perinatology · 2026Article
- Article
- Systematic review and meta-analysis of risk prediction models for retinopathy of prematurity in preterm infants.Biomedical reports · 2025Article
- Correlation between histologic chorioamnionitis and severe retinopathy of prematurity.Pediatric research · 2025Article
- Retinopathy of Prematurity and Risk of Structural Brain Abnormalities on Magnetic Resonance Imaging at Term Among Infants Born at Less Than or Equal to 32 Weeks of Gestation.The Journal of pediatrics · 2025Article
- Observational
- Increased risk of autism in extremely preterm children with a history of retinopathy of prematurity.Acta paediatrica (Oslo, Norway : 1992) · 2025Article
- Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity.Eye (London, England) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retinopathy of prematurity (ROP) and abnormal brain development share similar risk factors and mechanisms. There has been contrasting evidence on the association of ROP with adverse neurodevelopmental outcomes. Objective: We analysed the association between ROP at levels of severity and treatment with all neurodevelopmental outcomes until adolescence. Data source: We followed PRISMA guidelines and searched Medline and Embase between 1 August 1990 and 31 March 2022. Study selection and participants: Randomised or quasi-randomised clinical trials and observational studies on preterm infants (<37 weeks) with ROP [type 1 or severe ROP, type 2 or milder ROP, laser or anti-vascular endothelial growth factor (VEGF) treated] were included. Data extraction and synthesis: We included studies on ROP and any neurocognitive or neuropsychiatric outcomes. Outcomes: The primary outcomes were as follows: cognitive composite scores evaluated between the ages of 18 and 48 months by the Bayley Scales of Infant and Toddler Development (BSID) or equivalent; neurodevelopmental impairment (NDI; moderate to severe NDI or severe NDI), cerebral palsy, cognitive impairment; and neuropsychiatric or behavioural problems. The secondary outcomes were as follows: motor and language composite scores evaluated between the ages of 18 and 48 months by BSID or equivalent; motor/language impairment; and moderate/severe NDI as defined by the authors. Results: In preterm infants, "any ROP" was associated with an increased risk of cognitive impairment or intellectual disability [ Conclusion and relevance: Infants with "any ROP" had higher risks of cognitive impairment or intellectual disability, cerebral palsy, and behavioural problems. Anti-VEGF treatment increased the risk of moderate cognitive impairment. These results support the association of ROP and anti-VEGF treatment with adverse neurodevelopmental outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier: CRD42022326009.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.